Showing results (101-110 of 773) with videos related to

Sort By:
Pageof 78
Health Affairs (Project Hope)|March 4, 2015
Mandatory disclaimers on dietary supplements do not reliably communicate the intended issuesAaron S Kesselheim, John Connolly, James Rogers, et al.
JAMA Network Open|January 24, 2024
Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine CareDongzhe Hong, Jerry Avorn, Richard Wyss, et al.
Chest|October 14, 2003
Hetastarch and bleeding complications after coronary artery surgeryJerry Avorn, Minalkumar Patel, Raisa Levin, et al.
Health Affairs (Project Hope)|June 4, 2014
Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in childrenIan Larkin, Desmond Ang, Jerry Avorn, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 10, 2021
Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in FranceVéronique Raimond, Julien Mousquès, Jerry Avorn, et al.
Neurology|September 8, 2021
Discovery and Development of Pregabalin (Lyrica): The Role of Public FundingRachel Barenie, Jonathan Darrow, Jerry Avorn, et al.
American Journal of Epidemiology|July 1, 2005
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibrationTil Stürmer, Sebastian Schneeweiss, Jerry Avorn, et al.
JAMA Internal Medicine|September 19, 2022
Holding Pharmaceutical and Medical Device Executives Accountable as Responsible Corporate OfficersC Joseph Ross Daval, Jerry Avorn, Aaron S Kesselheim
The American Journal of Cardiology|August 25, 2004
Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarctionJerry Avorn, Eric Knight, David A Ganz, et al.
JAMA Internal Medicine|November 22, 2017
Use of Health Care Databases to Support Supplemental Indications of Approved MedicationsMichael Fralick, Aaron S Kesselheim, Jerry Avorn, et al.
Pageof 78